Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic With a whopping 7 approvals in the last two years, the field ...
Elbit Systems debuted today, during a media and analysts visit to its subsidiary, Elbit Systems Electro-optics Elop, the ENGAGER- a new advanced remote reconnaissance gathering system. Designed for ...
SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have ...
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) ...
As part of a new deal, Janux Therapeutics could receive up to $800 million in development, regulatory and commercial milestone payments from Bristol Myers Squibb. (Angus Liu/Fierce Pharma) Bristol ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer ...
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 ...
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results